Sai Parenterals Limited reported a standalone net profit of ₹8.9 crore for the quarter ended June 30, 2026, marking a 975% year-on-year increase from ₹0.8 crore in Q1FY26. This significant turnaround was driven by a 175% surge in revenue from operations to ₹52.8 crore, compared to ₹19.2 crore in the corresponding period of the previous fiscal year. On a consolidated basis, which includes the full quarter impact of its Australian subsidiary Noumed Pharmaceuticals, revenue reached ₹182.4 crore against ₹34.6 crore last year, while consolidated net profit stood at ₹7.9 crore.

The Board of Directors approved these unaudited financial results on August 11, 2026. Statutory Auditors R. Kabra & Co. LLP issued an unmodified limited review conclusion on the standalone and consolidated financial statements. The company’s equity shares were listed on the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on April 2, 2026; consequently, comparative data for Q1FY26 is presented as unaudited information to facilitate comparability. Management noted that the year-on-year comparison is not like-for-like as Noumed was consolidated with effect from November 12, 2025.

Beyond financial performance, the Board approved strategic shifts in capital allocation. The company will utilize ₹83.83 crore, originally earmarked for upgrading Unit I and Unit II manufacturing facilities, to acquire a 60% equity stake in Saicriti Pharma Private Limited. This acquisition involves a state-of-the-art critical care sterile injectable manufacturing facility at Gummadidala, Hyderabad, with a total estimated development cost of ₹215 crore. Additionally, ₹18.02 crore allocated for establishing a new Research & Development Centre will be redirected to acquire a 60% stake in Prathyak Laboratories Private Limited, an established pharmaceutical R&D platform. Both acquisitions are subject to shareholder approval.

Key Financial Metrics (Standalone)

Key Financial Metrics (Consolidated)

What the Numbers Show

The divergence between standalone and consolidated performance highlights the weight of international subsidiaries in the group’s overall profile. While standalone EBITDA margin expanded significantly to 29.8% from 20.9% in Q1FY26 due to operating leverage, consolidated EBITDA margin contracted slightly to 14.9% from 17.1% in the prior year period. This contraction was primarily driven by elevated air-freight costs in Australia arising from industry-wide shipping disruptions and the fact that the Noumed platform currently operates at distribution margins pending the commencement of in-house manufacturing at Adelaide. However, gross margins improved sequentially to 41.8% from 38.1% in Q4FY26, indicating that negotiated price revisions are beginning to offset raw material cost increases. The standalone entity contributed 31% of consolidated revenue but 61% of consolidated EBITDA, underscoring the higher profitability of domestic operations compared to the international distribution arm.

Strategic Acquisitions and Expansion

The Board’s decision to vary the use of IPO proceeds aims to accelerate capacity expansion and R&D capabilities. The acquisition of a 60% stake in Saicriti Pharma Private Limited allows the company to bypass the lengthy land allotment process required for greenfield projects within the Outer Ring Road of Hyderabad, where upgradations are no longer permitted under the Hyderabad Industrial Lands Transformation Policy. The new facility at Gummadidala will provide approximately 154.66 million units of injectable capacity, roughly 47% more than the original plan, with completion targeted for April 2027. Similarly, acquiring Prathyak Laboratories provides immediate access to a pipeline of 150 SKUs and a team of 28 research scientists, supporting the company’s strategy to build an IP-led business. Funding for the AUD 53 million Australian facility has been completed, with Phase 1 manufacturing expected from April 2027.

Management reaffirmed its full-year guidance of ₹750 crore in revenue for FY27 at an EBITDA margin of around 17%. The year is weighted towards the second half, with the first quarter representing approximately 24% of the annual target. As on June 30, 2026, debt stood at approximately ₹310 crore against March 2026 debt of ₹319 crore, with cash and cash equivalents of ₹184 crore. The gross debt-to-equity ratio remains comfortably placed at 0.6 times even at peak debt levels expected during the ongoing CAPEX and acquisition program.

Sai Parenterals Limited presented its investor update for the quarter ended June 30, 2026, on August 12, 2026, detailing a strategic shift towards regulated markets through a ₹571 crore capital expenditure programme. The company reported a consolidated net profit before tax of ₹11.9 crore for FY26, driven by the integration of Noumed Pharmaceuticals, which was consolidated with effect from November 12, 2025. Management emphasized that year-on-year comparisons are not like-for-like due to this recent acquisition, which adds significant revenue visibility through long-term contracts in Australia and New Zealand.

The Board has proposed a variation in the utilization of IPO proceeds under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The variation reallocates funds from capacity expansion of existing units to two new acquisitions: a 60% stake in Saicriti Pharma Private Limited for ₹83.83 crore and a 60% stake in Prathyak Laboratories Private Limited for ₹15.0 crore. These transactions aim to replace constrained injectable facilities within the Outer Ring Road (ORR) of Hyderabad with a new greenfield facility at Gummadidala and an operating R&D centre at Genome Valley. Shareholder approval is required for these changes.

Capital Expenditure and Facility Upgrades

The total capex programme stands at ₹571 crore, with the company’s own funded share remaining unchanged at ₹440 crore. The investment is distributed across four key projects:

Units I and II at Jeedimetla are scheduled for discontinuation upon commissioning of the new Saicriti facility. The Adelaide facility, supported by a AUD 20 million grant from the Australian Government, aims to shift production from outsourced distribution margins to higher manufacturing margins.

Operational Highlights and Market Position

Sai Parenterals operates across two verticals: Branded Generic Formulations and Contract Development and Manufacturing Organization (CDMO). Over 50% of consolidated revenue is contracted under long-term agreements in regulated markets. The private-sector revenue share rose from 39% in FY23 to 81% in FY26, indicating reduced reliance on tender-based sales. The company holds 599 approved registrations and has 67 dossiers under development, targeting patent expiries over the next three years.

Financial Performance Context

Consolidated cash generated from operations stood at ₹98.0 crore in FY26, compared to ₹33.7 crore in FY25. Net profit before tax was ₹11.9 crore in FY26 versus ₹19.9 crore in FY25. The decline in profitability despite higher operating cash flow reflects the initial integration costs and non-recurring items associated with the Noumed acquisition and ongoing capex investments. Cash and cash equivalents increased significantly to ₹417.0 crore at the end of FY26 from ₹2.1 crore in FY25, bolstered by financing activities totaling ₹595.7 crore.

What the Numbers Show

The financial data reveals a transitional phase where operational cash generation has improved substantially (₹98.0 crore in FY26 vs ₹33.7 crore in FY25), yet net profit before tax contracted (₹11.9 crore vs ₹19.9 crore). This divergence suggests that while core operations are generating stronger cash flows, the bottom line is currently impacted by integration expenses and the high capital intensity of the expansion programme. The substantial increase in cash reserves (₹417.0 crore) provides a buffer for the upcoming debt obligations linked to the Saicriti facility, which includes a ₹75.24 crore project debt component.